Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UXNFA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HPS157-039-002
|
|||||
| Synonyms |
HPS157 039 002
Click to Show/Hide
|
|||||
| Organization |
Oncomatryx Biopharma SL
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.08
|
|||||
| Antibody Name |
FAP hu36
|
Antibody Info | ||||
| Antigen Name |
Prolyl endopeptidase FAP (FAP)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
HPS157-039-002 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 0
|
%
|
Pancreatic adenocarcinoma PDX model (PDX: PAXF-736)
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
552
|
nM
|
CVCL_0317
|
Fibrosarcoma
|
| Half Maximal Inhibitory Concentration (IC50) |
964
|
nM
|
CVCL_0317
|
Fibrosarcoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0% | Negative FAP expression (FAP-) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
|
||||
| In Vivo Model | Pancreatic adenocarcinoma PDX model (PDX: PAXF-736) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 552 nM | Negative FAP expression (FAP-) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 964 nM | Positive FAP expression (FAP+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||